



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



ELSEVIER

**BIAM**  
 British Infection Association

[www.elsevierhealth.com/journals/jinf](http://www.elsevierhealth.com/journals/jinf)

## LETTERS TO THE EDITOR

**Severe respiratory disease with rhinovirus detection: Role of bacteria in the most severe cases**


Dear Editor,

We read with interest a recent paper in this Journal about how the nasopharyngeal bacterial burden may influence in the severity in infants with respiratory syncytial virus (RSV) bronchiolitis.<sup>1</sup> We performed a study which aim was to analyze the epidemiologic and clinical characteristics of patients with severe lower-respiratory-tract infection (LRTI) with Rhinovirus (RV) detection in comparison to the patients without RV detection in a pediatric intensive care unit (PICU), and the role of viral and/or bacterial co-detections as risk factors of severity. We observed that the severity was related with bacterial detection on tracheal aspirates, independently of fulfilling diagnostic criteria of bacterial pneumonia. These results are similar to those of Suarez-Arrabal et al. with RSV infection.

RV is the most common respiratory virus detected in all groups of age and probably the main agent causing acute respiratory infections in humans.<sup>2</sup> More than 30% of general admissions for acute LRTI in children lower than 5 years of age are caused by RV, and the number of admissions to PICU is not negligible.<sup>3,4</sup>

The study was conducted in a PICU of a pediatric tertiary care hospital (January 2012–December 2013). Epidemiologic and clinical data of admitted patients 6-month to 18 years-old, with severe LRTI (bronchospasm or bronchopneumonia) were consecutively and prospectively collected. Patients with chronic conditions, previous episodes of wheezing and nosocomial respiratory infection were excluded.

Severe LRTI was considered as that of those patients in need of admission to PICU for any of the following treatments: invasive (IMV) or non-invasive (NIV) mechanical ventilation; or high flow oxygen therapy with FiO<sub>2</sub> greater than or equal 0.6.

Suspected bacterial infection was defined as fever >38 °C with laboratory abnormality (Reactive C-Protein >70 mg/dl or Procalcitonin >1 ng/ml), and one or more thoracic radiography infiltrates, and antibiotic/s prescription during the first 24 h of admission. The total virus analyzed with a Real-Time PCR (Anyplex II RV16 detection (Seegene, South Korea)) in respiratory samples were:

Adenovirus (AdV), Influenza A virus (FluA), Influenza B virus (FluB), Parainfluenza virus 1 (PIV1), Parainfluenza virus 2 (PIV2), Parainfluenza virus 3 (PIV3), Parainfluenza virus 4 (PIV4), Rhinovirus A/B/C (HRV), RSV A/B, Bocavirus 1/2/3/4 (HBoV), Metapneumovirus (MPV), Coronavirus 229E (CoV 229E), Coronavirus NL63 (CoV NL63), Coronavirus OC43 (CoV OC43) and Enterovirus (HEV). Bacterial detection was defined as the growth of any bacteria ( $\geq 10^3$  colonies/field) in cultures of tracheal aspirate in patients who underwent invasive mechanical ventilation (MV).

There were recruited 96 patients with LRTI. In 66% RV was detected, similar to the literature.<sup>3,5</sup> No differences in severity (requirements of ventilatory support, length of ventilatory support and PICU stay) were found between patients infected with RV and patients with other viral detections. The main viral co-detection was RSV (4/11, 36%). No differences in severity between patients with RV and RV plus other viral co-detections were found (Table 1). Some series have described that RV could cause a more severe disease in comparison to other frequently detected viruses, such as Influenza and Respiratory Syncytial Virus (RSV).<sup>5</sup> In contrast, children with bronchiolitis and RV detection had a significantly shorter hospital length of stay as compared with children with RSV bronchiolitis in other series.<sup>6</sup> In our opinion, age, comorbidities<sup>5</sup> and differences in the diagnosis of included patients (bronchiolitis, bronchopneumonia, and bronchospasm) could be an important bias when interpreting these different results with regard to the severity of RV infection in comparison to other viruses. We want to remark that we didn't include children younger than 6 months, so the diagnosis of bronchiolitis was importantly avoided.<sup>7</sup>

The distribution of patients who met criteria for suspected bacterial infection was similar between those with or without RV. The rate of patients with positive tracheal aspirates cultures was also similar between groups (Table 1).

*With regard to variables leading to severity of LRTI in patients in whom RV was detected.* 16 of 55 (29%) patients with RV infection required a PICU stay over the 75th percentile of the total sample. There were not significant differences in the need for respiratory support with invasive IMV, non-invasive MV, nor the duration of these techniques between patients with RV and RV plus other viral co-detections (Table 1).

Considering only the 15 patients in whom cultures of tracheal aspirates were performed within the first 72 h of hospital admission, the 2 more severely ill patients, those who required HFOV, had  $\geq 10^3$  colonies/field of bacterial

**Table 1** Epidemiological characteristics, clinical variables and microbiological data of children with lower-respiratory-tract infection and Rhinovirus detection in comparison to children in whom other viruses were detected.

	No rhinovirus	Rhinovirus		p-value*	p-value†	Total
		As sole viral detection	With other viral detection			
<i>n</i>	41	44	11	—		96
<b>Epidemiology</b>						
<i>Age</i>						
6 m–2 y	26 (64%)	23 (52%)	8 (72%)			57 (59%)
2–5 y	10 (24%)	14 (32%)	3 (27%)			27 (28%)
>5 y	5 (12%)	7 (16%)	0 (0%)			12 (13%)
Median age (month-old)‡	15.0 (12.0–9.5)	20.5 (9.2–42.2)	16.0 (9.0–31.0)	0.30	0.57	18 (11.0–35.8)
<i>Sex</i>						
Male	22 (54%)	26 (59%)	5 (45%)	0.50	0.79	53 (55%)
<b>Clinical variables</b>						
Fever	27 (66%)	21 (48%)	6 (55%)	0.69	0.10	53 (55%)
Chest-X-ray with ≥1 quadrant opacities	25 (61%)	26 (59%)	5 (45%)	0.66	0.80	56 (58%)
PRISM score at PICU admission‡	3 (1–4)	3 (0–6)	3 (0–3)	0.23	0.86	3 (0–5)
<b>Ventilatory support</b>						
<i>Requirements of</i>						
- NIV-exclusively	22 (54%)	26 (59%)	7 (64%)	0.97	0.53	55 (57%)
- CMV	13 (32%)	14 (32%)	4 (36%)	0.91	0.91	31 (32%)
- HFOV	4 (10%)	4 (10%)	0 (0%)	0.64	0.66	8 (8%)
<i>Days of ventilatory support‡</i>						
- NIV	2.5 (1.5–4.2)	1.8 (1.3–3.5)	2.2 (1.2–4.0)	0.81	0.31	2.3 (1.5–3.9)
- CMV	4.9 (2.8–8.3)	5.0 (2.9–8.3)	10.0 (4.5–14.7)	0.19	0.53	5.0 (3.0–8.4)
- Total	3.2 (1.8–6.1)	3.3 (1.5–7.7)	4 (1.9–11)	0.60	0.47	3.3 (1.6–11.2)
PICU stay (days)‡	4 (3–7)	4 (3–10)	5 (3–12)	0.79	0.48	4 (3–8)
PICU stay >75th percentile	7 (17%)	12 (27%)	4 (36%)	0.71	0.17	23 (24%)
<b>Microbiological data</b>						
Suspected bacterial infection	12 (29%)	9 (20%)	3 (27%)	0.69	0.40	24 (25%)
Bacterial detection in tracheal aspirate	8/16 (50%)	8/13 (61%)	1/2 (50%)	1.00	0.57	17/31 (55%)

PRISM III indicates Pediatric Risk Score of Mortality III; PICU, Pediatric Intensive Care Unit; CMV, Conventional Mechanical Ventilation; NIV, Non-Invasive Ventilation; HFOV, High Frequency Oscillatory Ventilation. \* Rhinovirus as sole viral detection vs Rhinovirus plus other viral detections, † Rhinovirus vs no Rhinovirus, ‡ Median (interquartile range). Proportions between the groups were compared using Pearson Chi-square or Fisher exact test when the expected count in any category was <5. For continuous variables, the Mann–Whitney U test was performed.

grown (*Staphylococcus aureus* and *Haemophilus influenzae*). All the patients (9) with confirmed bacterial growth required a long PICU stay, whereas only 2 patients of 6 without bacterial detection required it;  $p = 0.01$ . Of them, 2/9 (22%) do not fulfilled the criteria of bacterial infection (Table 2).

These results are in accord to those reported by Kloepfer et al., who described that children with both, RV and bacterial detection in nasal samples, experienced greater airway inflammation,<sup>8</sup> similarly to the results of Suárez-Arabal et al.<sup>1</sup> We feel that bacterial carriage in children with virus infection influences either in predisposing to bacterial pneumonia more easily (but 2 of 9 patients in our study do not fulfilled this criteria) or to suffer a greater airway inflammation such as Yu et al.<sup>9</sup> Recently, Hofstra et al. performed an experimental study in healthy volunteers infected with RV. They observed changes of upper respiratory-tract microbiota that could help explain why RV infection predisposes to bacterial otitis media, sinusitis

and pneumonia.<sup>10</sup> For this reason, bacterial carriage and, moreover, bacterial infection must be considered when analyzing the severity of rhinovirus infection in comparison to other viruses, and it is often missed.

The main limitations of this study are the small sample size and the difficulty in distinguishing bacterial growth in the context of low-respiratory-tract colonization or bacterial pneumonia that did not meet the mentioned criteria of bacterial infection.

To conclude, this study did not found differences in epidemiologic and clinical variables between children infected with RV and children with other viral infections. The study also highlights the important role of bacterial detection in tracheal aspirates, even without fulfilling criteria of bacterial pneumonia: all the intubated patients with RV infection and bacterial grown on tracheal aspirates required for a long PICU stay.

Differences in the severity of patients with RV, with or without viral co-detection were not found.

**Table 2** Epidemiological data and variables of severity in relation to microbiological data of children who underwent invasive mechanical ventilation with rhinovirus infection.

	Rhinovirus				<i>P</i> <sup>a</sup>
	No criteria of suspected bacterial infection		Fulfilling criteria of suspected bacterial infection		
	Without bacterial detection in tracheal aspirates	With bacterial detection in tracheal aspirates	Without bacterial detection in tracheal aspirates	With bacterial detection in tracheal aspirates	
<i>n</i>	6	2	0	7	–
<i>Age</i>					
6 m–2 y	2	2	–	3	
2–5 y	3	0	–	2	
>5 y	1	0	–	2	0.49
<i>Sex</i>					
Male	4	0	–	5	0.17
<i>Severity variables</i>					
Days of MV (median, IQR)	4.2 (3.0–12.8)	24.6 (21.4–27.7)	–	9.0 (8.1–10.6)	0.04
Need of HFOV	0	1	–	1	0.19
PICU stay >75th percentile	2	2	–	7	0.01
<i>Tracheal aspirate microbiological data</i>					
Viruses	5 RV as sole viral detection 1 RV + Parainfluenza Virus 3	1 RV as sole viral detection 1 RV + Parainfluenza Virus 3 + Metapneumovirus	–	7 RV as sole viral detection	
Bacteria	–	1 <i>Staphylococcus aureus</i> 1 <i>Pseudomonas aeruginosa</i>	–	2 <i>Escherichia coli</i> 2 <i>Pseudomonas aeruginosa</i> 2 <i>Haemophilus influenzae</i> 1 <i>Moraxella catarrhalis</i>	

Suspected bacterial infection criteria: fever >38 °C with laboratory abnormality (Reactive C-Protein >70 mg/dl or Procalcitonin >1 ng/ml) and one or more thoracic radiography infiltrates and antibiotic/s prescription during the first 24 h of admission.

RV, Rhinovirus; MV, Mechanical Ventilation; HFOV, High Frequency Oscillatory Ventilation; PICU, Pediatric Intensive Care Unit.

<sup>a</sup> Proportions between the groups were compared using Pearson Chi-square test. For continuous variables, the Kruskal–Wallis analysis was performed.

## Conflict of interest

The authors declare that there are no conflicts of interest.

## References

- Suárez-Arrabal MC, Mella C, López SM, Brown NV, Hall MW, Hammond S, et al. Nasopharyngeal bacterial burden and antibiotics: influence on inflammatory markers and disease severity in infants with respiratory syncytial virus bronchiolitis. *J Infect* 2015;**71**:458–69.
- Ruuskanen O, Waris M, Ramilo O. New aspects on human rhinovirus infections. *Pediatr Infect Dis J* 2013;**32**:553–5.
- Louie J, Roy-Burman A, Guardia-LaBar L, Boston EJ, Kiang D, Padilla T, et al. Rhinovirus associated with severe lower respiratory tract infections in children. *Pediatr Infect Dis J* 2009;**28**:337–9.
- Cheuk D, Tang I, Hung Chan K, Woo PC, Peiris MJ, Chiu SS. Rhinovirus infection in hospitalized children in Hong Kong. *Pediatr Infect Dis J* 2007;**26**:995–1000.
- Asner S, Petrich A, Hamid J, Mertz D, Richardson SE, Smieja SM. Clinical severity of Rhinovirus/Enterovirus compared to other respiratory viruses in children. *Influenza Other Respir Viruses* 2014;**8**:436–42.
- Mansbach JM, Piedra PA, Teach SJ, Sullivan AF, Forgey T, Clark S, et al. Prospective multicenter study of viral etiology and hospital length of stay in children with severe bronchiolitis. *Arch Pediatr Adolesc Med* 2012;**166**:700–6.
- Korppi M, Koponen P, Nuolivirta K. Upper age limit for bronchiolitis: 12 months or 6 months? *Eur Respir J* 2012;**39**:787–8.
- Kloepfer KM, Lee WM, Pappas TE, Kang TJ, Vrtis RF, Evans MD, et al. Detection of pathogenic bacteria during rhinovirus infection is associated with increased respiratory symptoms and asthma exacerbations. *J Allergy Clin Immunol* 2014;**133**:1301–7.
- Yu D, Wei L, Zhengxiu L, Jian L, Lijia W, Wei L, et al. Impact of bacterial colonization on the severity, and accompanying airway inflammation, of virus-induced wheezing in children. *Clin Microbiol Infect* 2010;**16**:1399–404.
- Hofstra JJ, Matamoros S, van de Pol MA, de Weyer B, Tanck MW, Wendt-Knol H, et al. Changes in microbiota during experimental human Rhinovirus infection. *BMC Infect Dis* 2015 Aug 14;**15**:336. <http://dx.doi.org/10.1186/s12879-015-1081-y>.

Georgina Armero

*Pediatric Intensive Care Unit, Sant Joan de Déu Hospital, Esplugues de Llobregat, Barcelona, 08950, Spain*  
E-mail address: [garmero@sjdhospitalbarcelona.org](mailto:garmero@sjdhospitalbarcelona.org)  
(G. Armero)

Cristian Launes

*Pediatric Department, Hospital Sant Joan de Déu, Paediatric Infectious Diseases Research Group, Institut d'investigació pediàtrica Hospital Sant Joan de Déu, CIBERESP, Esplugues de Llobregat, Barcelona, 08950, Spain*  
E-mail address: [claunes@sjdhospitalbarcelona.org](mailto:claunes@sjdhospitalbarcelona.org)  
(C. Launes)

Lluisa Hernández-Platero

Carme Alejandre

*Pediatric Intensive Care Unit, Sant Joan de Déu Hospital, Esplugues de Llobregat, Barcelona, 08950, Spain*  
E-mail addresses: [lhernandez@sjdhospitalbarcelona.org](mailto:lhernandez@sjdhospitalbarcelona.org)  
(L. Hernández-Platero), [calejandre@sjdhospitalbarcelona.org](mailto:calejandre@sjdhospitalbarcelona.org) (C. Alejandre)

Carmen Muñoz-Almagro

*Molecular Microbiology Department, Hospital Sant Joan de Déu, Paediatric Infectious Diseases Research Group, Institut d'investigació pediàtrica Hospital Sant Joan de Déu, CIBERESP, Esplugues de Llobregat, Barcelona, 08950, Spain*  
E-mail address: [cma@sjdhospitalbarcelona.org](mailto:cma@sjdhospitalbarcelona.org) (C. Muñoz-Almagro)

Iolanda Jordan\*

*Pediatric Intensive Care Unit, Sant Joan de Déu Hospital, Paediatric Infectious Diseases Research Group, Institut d'investigació pediàtrica Hospital Sant Joan de Déu, CIBERESP, Esplugues de Llobregat, Barcelona, 08950, Spain*

\*Corresponding author. Sant Joan de Déu Hospital, Sant Joan de Déu Hospital, PICU, Pss Sant Joan de Déu number 2, Esplugues de Llobregat, Barcelona, 08950, Spain.  
E-mail address: [ijordan@sjdhospitalbarcelona.org](mailto:ijordan@sjdhospitalbarcelona.org)  
(I. Jordan)

Accepted 15 July 2016

<http://dx.doi.org/10.1016/j.jinf.2016.07.010>

© 2016 The British Infection Association. Published by Elsevier Ltd. All rights reserved.

## Seroepidemiology of Coxsackievirus A6, Coxsackievirus A16, and Enterovirus 71 infections in infants and children: A prospective cohort study in Jiangsu, China



Recent articles in this Journal have referred to the problems caused by enteroviruses<sup>1</sup> particularly in China.<sup>2</sup> Hand, foot, and mouth disease (HFMD) has been a serious public health problem in the Asia-Pacific Region.<sup>1–4</sup> Human enteroviruses A (HEV-A) species with Enterovirus 71 (EV-A71) and Coxsackievirus A16 (CV-A16) have accounted for major HFMD outbreaks worldwide.<sup>3,4</sup> Recently, Coxsackievirus A6 (CV-A6), another virus from HEV-A, has also been recognized as an important pathogen for HFMD.<sup>2,4</sup> Infants and children are susceptible to CV-A6 infection,<sup>4</sup> but seroepidemiological studies on CV-A6 are lacking. In this study, neutralizing antibodies (NtAbs) in serum samples from a prospective cohort study were analyzed to reveal the epidemic characteristics of CV-A6, CV-A16 and EV-A71 in the context of HFMD epidemic in infants and children.

A total of 319 participants aged 6–35 months old, who were previously enrolled in a clinical trial to assess the immunogenicity of EV-A71 vaccine in Jiangsu Province (clinical trial No. NCT01508247), were followed for two years (January, 2012–January, 2014). Sera were collected at the start of study (January 2012), in March 2012, September 2012 and January 2014. From this cohort, 180 participants whose sera were collected at all four scheduled visits were analyzed in this study. Altogether, there were 117 males and 63 females, while 41 participants were in the infant group (aged 6–11 months) and 139 participants were in the child group (aged 12–35 months). Titers of NtAbs